Exelixis

Name

Exelixis

Legal name

Exelixis, Inc.

Website

https://exelixis.com

Company type

Public

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Oncology drug development
• Tyrosine kinase inhibitors
• Antibody-drug conjugates
• Cancer therapeutics
• Biopharmaceutical products

Headquarters

HQ city

Alameda

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. CABOMETYX net product revenues: Primary revenue driver from cabozantinib franchise. Exelixis commercializes CABOMETYX directly in the US market. The franchise generated approximately $2.12 billion in U.S. net product revenues for FY2025, representing 17% year-over-year growth. Q1 2026 cabo franchise generated $764 million in revenue.
2. Collaboration and partnership revenue: Revenue from licensing agreements with international partners including Ipsen (commercializing cabozantinib outside US/Japan), Takeda (Japan), and various co-development collaborations with pharmaceutical companies.
3. Government contracts/NIH: Clinical trials sponsored in part by the National Cancer Institute and other governmental bodies supporting oncology research programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Exelixis is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes small molecule and biotherapeutic oncology medicines. Its core franchise is CABOMETYX (cabozantinib), an oral tyrosine kinase inhibitor approved across renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors, generating approximately $2.12 billion in FY2025 U.S. net product revenues. The company is building a second franchise around zanzalintinib (XL092), a next-generation TKI with an FDA NDA accepted for metastatic colorectal cancer, alongside a pipeline of antibody-drug conjugates, bispecific antibodies, and USP1 inhibitors.

Product overview

Exelixis is a commercial-stage oncology-focused biopharmaceutical company that has evolved into a multi-platform cancer company developing both small molecule therapeutics and biotherapeutics. The company's core commercial portfolio centers on CABOMETYX (cabozantinib), an oral tyrosine kinase inhibitor approved across multiple cancer indications including renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and neuroendocrine tumors. The company is building zanzalintinib as its next-generation franchise with an NDA accepted for metastatic colorectal cancer. The pipeline includes novel compounds across multiple modalities: small molecules (XL309 USP1 inhibitor), antibody-drug conjugates (XB010, XB371, XB773), and bispecific antibodies (XB628), along with partnered programs including COTELLIC (cobimetinib) and MINNEBRO (esaxerenone).

Differentiator

Problem solved

Functional benefit

Brands

• Zanzalintinib (XL092): Next-generation TKI targeting MET/VEGFR/AXL/MER - the company's lead pipeline candidate positioned as a potential second oncology franchise
• XL309
• XB010
• XB628
• XB371
• ADU-1805

Products and services

• CABOMETYX (cabozantinib) An oral tyrosine kinase inhibitor targeting MET, VEGFR, AXL, and MER receptors, approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and advanced neuroendocrine tumors.
• COMETRIQ (cabozantinib) An oral tyrosine kinase inhibitor formulation of cabozantinib approved for the treatment of patients with progressive, metastatic medullary thyroid cancer.
• Zanzalintinib (XL092) A next-generation oral tyrosine kinase inhibitor targeting MET, VEGFR, AXL, and MER, being developed as Exelixis's second oncology franchise with FDA NDA accepted for metastatic colorectal cancer and Phase 3 trials ongoing in RCC, neuroendocrine tumors, and other solid tumors.
• XL309 (formerly ISM3091) A clinical-stage small molecule inhibitor of USP1 with broad applicability in BRCA-mutant tumors including forms of ovarian, prostate, and breast cancer, licensed from Insilico Medicine.
• XB010 A next-generation 5T4-MMAE antibody-drug conjugate in Phase 1 clinical trials for solid tumors.
• XB628 A PD-L1 + NKG2A bispecific antibody in Phase 1 clinical trials for solid tumors.
• XB371 A tissue factor (TF) topoisomerase inhibitor antibody-drug conjugate in Phase 1 clinical trials for solid tumors.
• XB773 A DLL3-targeted topoisomerase inhibitor antibody-drug conjugate in preclinical development.
• COTELLIC (cobimetinib) A MEK inhibitor partnered with Genentech/Roche, marketed in combination with other therapies for melanoma.
• MINNEBRO (esaxerenone) An oral non-steroidal selective mineralocorticoid receptor blocker developed with Daiichi Sankyo, marketed in Japan for hypertension.

Quantifiable outcome

• CABOMETYX showed 20% mortality risk reduction in metastatic colorectal cancer (STELLAR-303)
• +5 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Merck (MSD)coreStrategic or Co-development Partner · 19 May 2026Clinical development collaboration for STELLAR-316 Phase 3 trial evaluating zanzalintinib with KEYTRUDA in resected stage II/III colorectal cancer. Also partnered on LITESPARK-033 and LITESPARK-034 trials combining zanzalintinib with belzutifan in RCC.
• NateracoreStrategic or Co-development Partner · 7 January 2026Collaboration on STELLAR-316 trial using Natera's Signatera MRD assay to identify and monitor MRD-positive colorectal cancer patients for zanzalintinib treatment.
• Bristol Myers SquibbcoreStrategic or Co-development PartnerClinical collaboration evaluating cabozantinib with nivolumab and ipilimumab, and zanzalintinib with nivolumab/relatlimab and nivolumab/ipilimumab combinations in advanced solid tumors.
• Catalent (Redwood Bioscience)coreTechnology or IntegrationCollaboration using SMARTag site-specific bioconjugation technology for ADC development. Exclusive license to three target programs with lead antibody/ADC candidates.
• Daiichi SankyominorStrategic or Co-development PartnerCollaboration targeting mineralocorticoid receptor (MR). Compound esaxerenone (CS-3150) developed for hypertension.
• Insilico MedicinecoreTechnology or IntegrationExclusive license agreement granting global rights to XL309 (ISM3091), a USP1 inhibitor for BRCA-mutant tumors, along with other USP1-targeting compounds.
• IpsencoreChannel Partner/ Reseller/ DistributorExclusive licensing agreement for commercialization and further development of cabozantinib in all geographies outside US and Japan. Ipsen is Exelixis' global partner for international markets.
• Roche/GenentechcoreStrategic or Co-development PartnerCobimetinib out-licensing and clinical collaborations evaluating cabozantinib and zanzalintinib with atezolizumab (Tecentriq).
• Sairopa B.V.minorStrategic or Co-development PartnerExclusive clinical development and option agreement for ADU-1805, a SIRPα-targeting monoclonal antibody, with option to acquire pending Phase 1 results.
• TakedacoreChannel Partner/ Reseller/ DistributorExclusive license for commercialization and development of cabozantinib in Japan.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Deciphera Pharmaceuticals: Specialty oncology company developing kinase inhibitors (e.g., ripretinib/QINLOCK for GIST) targeting cancer biology. Highly comparable to Exelixis in commercial-stage TKI franchise strategy, specialty pharmacy distribution model, and focus on expanding indications across tumor types.
• Blueprint Medicines: Targeted oncology company with FDA-approved kinase inhibitors (AYVAKIT, GAVRETO) and a pipeline of genomically-defined cancer therapies. Directly comparable to Exelixis in precision oncology strategy, kinase-inhibitor focus, and indication-by-indication label expansion.
• Cogent Biosciences: Clinical-stage oncology company developing kinase inhibitors (bezuclastinib for systemic mastocytosis and GIST). Comparable in kinase-inhibitor focus, mid-cap oncology profile, and pipeline diversification strategy aimed at multiple solid tumor and hematologic indications.
• Mirati Therapeutics: Targeted oncology company with KRAZATI (adagrasib), a KRAS G12C inhibitor approved for NSCLC. Comparable in targeted oncology strategy, focused commercial footprint on biomarker-defined populations, and acquired by Bristol Myers Squibb in 2024 — illustrating the M&A exit pathway for specialty oncology companies.

Broad incumbents

• Bristol Myers Squibb: Large oncology incumbent with checkpoint inhibitor franchise (Opdivo, Yervoy) and multiple targeted therapies. Directly relevant as Exelixis's combination partner (cabozantinib + nivolumab/ipilimumab) and as a competitor in RCC and other solid tumors with IO/TKI regimens.
• Merck & Co. Global pharmaceutical leader with KEYTRUDA as the dominant checkpoint inhibitor. Highly relevant as Exelixis's clinical development partner for zanzalintinib + KEYTRUDA in CRC (STELLAR-316) and RCC combinations, and as a competitor setting the standard of care in oncology.
• Pfizer: Diversified pharma with significant oncology portfolio including BAVENCIO (avelumab), IBRANCE, and several TKIs. Comparable as a competitor in RCC (BAVENCIO + axitinib) and a broader oncology player, with larger scale and broader indication breadth than Exelixis.
• AstraZeneca: Global oncology leader with TAGRISSO (osimertinib), IMFINZI, ENHERTU (ADC), and LYNPARZA. Comparable as a broad oncology incumbent competing in RCC (IMFINZI combinations) and increasingly in ADC and TKI spaces where Exelixis is building pipeline presence.

Regional players

• Ipsen: European-headquartered specialty pharma with oncology focus (including ex-US CABOMETYX commercialization for Exelixis). Directly relevant as Exelixis's primary international commercial partner, and as a comparable specialty oncology player in EU markets with similar target product profiles.
• Takeda Pharmaceutical: Japanese-headquartered global pharma with significant oncology presence and the Japan commercial partner for CABOMETYX. Comparable as a regional oncology incumbent and as Exelixis's Japanese distribution partner, with some overlap in kinase-inhibitor and rare oncology strategies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Exelixis-Inc-184812744547
• LinkedInlinkedin.com/company/exelixis
• Xx.com/exelixisinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exelixis